FDA gives tentative approval for extended-release capsules of MDD treatment

The FDA has granted tentative approval to Zydus Pharmaceuticals Inc. to market extended-release capsules of levomilnacipran, a treatment for major depressive disorder, the company announced in a press release.

The extended-release capsules will be available in 20 mg, 40 mg, 80 mg and 120 mg doses, the release stated.

Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor approved for the treatment of major depressive disorders in adults.